Kneat
Kneat Inc. allows regulated organizations to move from paper-based validation to intelligent, digitized, and paperless solutions. They provide expert, up-to-date, in-depth, and reliable knowledge and services about easy implementation of GMP solutions. Numus coordinated the public listing of Kneat on the TSX-CV via a reverse takeover. Since the public listing, Numus has coordinated multiple private placements for the company. Since going public, Kneat has raised over $60mil and the the software was onboarded by 8 of the top 10 largest pharmaceutical companies globally.
On August 11, 2026, kneat.com, inc. (“Kneat”) announced that its sale to an affiliate of Thoma Bravo, L.P. to acquire all of the issued and outstanding common shares of Kneat was completed. Under the terms of the Arrangement Agreement, shareholders of Kneat are entitled to receive C$6.50 per share in cash for each Kneat share they own. As Kneat is now a privately held company, its shares have ceased trading.
https://investors.kneat.com/
